The emergence of multidrug resistant (MDR) pathogenic bacteria is jeopardizing the value
of antimicrobials, which had previously changed the course of medical science. In this study …

The emergence of multidrug-resistant Gram-negative bacteria that cause nosocomial
infections is a growing problem worldwide. Colistin was first introduced in 1952 and was …

A synthetic antimicrobial peptide was identified as a possible candidate for the development
of a new antibacterial drug. The peptide, SET-M33L, showed a MIC90 below 1.5 μM and 3 …

Because few, if any, new antibiotics with activity against multidrug-resistant Gram-negative
bacteria will be available within the next several years, it is essential that colistin is used in …

Background: Infections caused by multi-drug-resistant Gram-negative bacteria, particularly
Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae, that …

Objective Despite its use was abandoned several decades ago, the polycationic peptide
colistin has become the last hope to treat severe infections caused by multidrug-resistant …

Resistance to colistin, a polypeptide drug used as an agent of last resort for the treatment of
infections caused by multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram …

The increasing prevalence of multidrug-resistant Gramnegative bacteria has stimulated the
potential indication of colistin in life-threatening infections. In recent studies, colistin has …

Colistin is increasingly used as last-line therapy against Gram-negative pathogens. The
pharmacokinetic (PK)/pharmacodynamic (PD) index that best correlates with the efficacy of …

Objectives This study investigated the exposure–response relationships between unbound
colistin in plasma and antibacterial activity in mouse thigh and lung infections. Methods …